Description: Nuformix PLC, formerly Levrett PLC, is a United Kingdom-based pharmaceutical development company. The Company uses cocrystal technology to develop drugs with programs in oncology supportive care and fibrosis. It uses cocrystal technology to re-engineer the crystalline form of drugs. Its clinical pipeline includes NXP001 and NXP002. Its pre-clinical pipeline includes NXP003. It is developing NXP001 for oncology supportive care. It is developing NXP002 for the treatment of multiple fibrotic diseases. NXP003 targets a mechanism understood to confer resistance to immuno-oncology, chemotherapy and radiotherapy cancer treatments.
Home Page: www.nuformix.com
NFX Technical Analysis
60 Gracechurch Street
London,
EC3V 0HR
United Kingdom
Phone:
44 1223 627222
Officers
| Name | Title |
|---|---|
| Dr. Joanne M. Holland | Consultant |
| Dr. Daniel John Gooding | Exec. Director |
| Mr. Benjamin Harber | Company Sec. |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5097 |
| Price-to-Sales TTM: | 47.5237 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 4 |